Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Sanwa Kagaku Kenkyusho

2

Pfizer

420

Eli Lilly

239

Merck

238

GlaxoSmithKline

197

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Aldose reductase

1

Dipeptidyl peptidase IV

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Colorectal cancer

1

Diabetic neuropathy

1

Type 2 diabetes mellitus

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

DRUG BANK

2

EPA CompTox

2

EVMPD

2

FDA UNII

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ANAGLIPTIN

K726J96838

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dipeptidyl peptidase IV

Conditions:

Type 2 diabetes mellitus

Anagliptin is a DPP-4 inhibitor developed for the treatment of type 2 diabetes mellitus. The drug was approved in Japan under the name Suiny and now it is being tested in the USA.

FIDARESTAT

8SH8T1164U

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Aldose reductase

Conditions:

Diabetic neuropathy

Colorectal cancer

Fidarestat (SNK-860) is an aldose reductase inhibitor codeveloped by Sanwa Kagaku, NK Curex, and Sankyo for the treatment of distal symmetric polyneuropathy (DSP). In a Phase III trial, 279 patients with DSP were randomized to receive fidarestat (1 m...

g daily) or placebo for 52 weeks. Evaluation of efficacy was based on changes in clinical symptoms (numbness, pain, rigidity, alterations in temperature perception, paresthesia, hypesthesia, and weakness) as well as changes in electrophysiological measurements such as F-wave NCV. Five of six electrophysiological measures assessing function in motor nerves showed statistically significant improvement from baseline within the treatment group; a comparison of the placebo and treatment groups on these measures, however, showed the statistical difference on only two of the six measures. Two electrophysiological measures of sensory function failed to show a statistically significant difference from baseline in the fidarestat group. Statistically significant improvements over placebo were noted on several measures of subjective symptoms (e.g., numbness of upper extremities, decreased tactile sensitivity in lower extremities, paresthesia in the sole), with a greater divergence between the two groups associated with the duration of treatment. The incidence of adverse events was 5.8% in the fidarestat group and 5% in the placebo group and no serious adverse events were noted.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1